Consensus and controversies in the definition, assessment, treatment and monitoring of BTcP: results of a Delphi study
-
-
[1] Hospital Universitario Puerta de Hierro
Hospital Universitario Puerta de Hierro
Madrid, España
-
[2] Hospital Universitario Virgen de la Macarena, España
-
[3] Hospital Germans Trias i Pujol, España
-
[4] TEVA Pharma, Madrid, España
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 18, Nº. 11 (November 2016), 2016, págs. 1088-1097
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
- Dialnet Métricas: 4 Citas
-
Resumen
Introduction There is no unanimous consensus on the clinical features to define breakthrough cancer pain (BTcP). The current project aimed to investigate the opinion of a panel of experts on cancer pain on how to define, diagnose, assess, treat and monitor BTcP.
Materials and methods A two-round Spanish multi-centre exploratory Delphi study was conducted with medical experts (n = 90) previously selected from Medical Oncology Services, Radiation Oncology, Palliative Care/Home Care Teams, and Pain Units. The study intended to seek experts’ consensus and to define a set of recommendations for the management of BTcP.
Results It was generally agreed that, definition of BTcP implies that baseline pain should be controlled (84 %), although not necessarily with opioids (only 30 %); there must be exacerbations (98.9 %); the duration of each episode should last <1 h (70 %); the intensity of pain ≥7 out of 10 (67.8 %); and the number of flares per day should not be less than four. All participants supported the use of the Davies algorithm for the diagnosis. The use of a ‘Patient Diary’ was highly recommended. The optimal treatment should have a rapid onset, a short-acting analgesic effect (1–2 h) and transmucosal nasal or oral administration. It was considered very important to develop protocols for the management of cancer pain.
Conclusions The present Delphi study identified a set of recommendations to define, assess and monitor BTcP.
